Adstiladrin, whose active substance is nadofaragene firadenovec, is a medicine intended for humans. A European Public Assessment Report (EPAR) exists for this medicine. The current status of the EPAR is "Opinion". This means that the drug is being evaluated. The EPAR document provides information to the public about the evaluation of the medicine by the European Medicines Agency (EMA). The EPAR summarizes the data and evidence that EMA used to support its recommendations regarding the use of the medicine.